Beckman Coulter and Abbott are Dominating the U.S. Clinical Chemistry Analyzer Market in 2020

U.S. Clinical Chemistry Analyzer Market is expected to grow with the CAGR of 6.4% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @

U.S. clinical chemistry analyzer market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the U.S. clinical chemistry analyzer market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio. For instance, in September 2020, F. Hoffmann-La Roche Ltd announced the launch of antibody test for markets accepting the CE marking. The test can be used to quantitatively measure the antibodies in people who have exposed to SARS Cov-2 and can play a vital role in vaccine clinical trial as well as help clinicians access patients’ immune response. The development has helped in increasing the product portfolio of the company.

Beckman Coulter, Inc. (a subsidiary of Danaher), is dominating player in the U.S. Clinical Chemistry Analyzer Market. The other key players existing in the market includes Abbott, Siemens Healthcare GmbH (a subsidiary of Siemens Healthineers), Randox Laboratories Ltd., F. Hoffmann-La Roche Ltd, ELITechGroup, Thermo Fisher Scientific Inc., HORIBA, Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Ortho Clinical Diagnostics (a subsidiary of Carlyle Group L.P.), Trivitron Healthcare, Nova Biomedical, Medica Corporation, Sysmex (a subsidiary of Sysmex Corporation), BioSystems Diagnostics Pvt. Ltd., AMS Alliance, ALCOR Scientific Inc., Teco Diagnostics, DiaSys Diagnostic Systems GmbH and Sekisui Diagnostics, among others.

U.S. Clinical Chemistry Analyzer MarketBeckman Coulter, Inc.

Beckman Coulter, Inc. has headquartered in California, U.S. was founded in 1935. The company focuses on providing diagnostic systems which are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. The product categories are life sciences, diagnostics, environment and applied solutions and market focused category is diagnostics.

For instance,

  • In November 2020, Beckman Coulter, Inc. launched Access SARS-CoV-2 Immunoglobulin M (IgM) assay. This assay can run on company manufactured analysers which can process about 200 samples per hour. The introduction of these assays which are compatible with the analysers will drive the growth of the market.

The company has presence in North America, South America, Europe, Asia-Pacific, Middle and Africa.


Abbott headquartered in Illinois, U.S. was founded in year 1888. The company provides personalized solutions across clinical chemistry, coagulation, hematology, immunoassay, transfusion medicine, point of care, rapid diagnostics, lab automation and molecular diagnostics. The product categories are cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition, medicine and market focused category is diagnostics.

For instance,

  • In September 2020, Abbott’s received CE mark for FREESTYLE LIBRE 3 System which can be placed on the back of the upper arm and can analyse blood glucose levels without pricks. It is the smallest device and easy to use thus it will fuel the growth of the market.

The company has wide global presence across the world as Asia-Pacific, Europe, Middle East and Africa, Africa, Americas with its various subsidiaries such as Alere Inc. (U.S.), Abbott India Ltd (India), Panbio Ltd (Australia), CardioMEMS (U.S.), Abbott Canada (Canada), Abbott Japan Co., Ltd. (Japan), among others.